GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.
from WSJ.com: US Business http://ift.tt/2btMH52
via IFTTT
No comments:
Post a Comment